 |
9 Diseases |  |
0 Trials |
|
0 Trials |  |
458 News |  |
- | naproxen Sodium ER (BAYH6689) / Bayer
Journal: Development and evaluation of naproxen-loaded sericin/alginate beads for delayed and extended drug release using different covalent crosslinking agents. (Pubmed Central) - May 15, 2021
The incorporation of the drug could be confirmed by the techniques of characterization of X-ray diffraction (XRD), scanning electron microscopy (SEM) and Fourier transform infrared spectroscopy (FTIR), as well as drug compatibility with the polymer matrix. In addition, particles of suitable size for multiparticulate systems were obtained and with higher thermal stability when compared to the pure drug.
- | naproxen Sodium ER (BAYH6689) / Bayer
Journal: The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen or Naproxen: a Secondary Analysis of the PRECISION Randomized Controlled Clinical Trial. (Pubmed Central) - Dec 16, 2017
Among patients with symptomatic arthritis who had moderate to high risk of cardiovascular events, approximately 1 in 20 experienced a major toxicity over 1 to 2 years. Patients using naproxen or ibuprofen experienced significantly higher risk of major toxicity than those using celecoxib.
- | naproxen Sodium ER (BAYH6689) / Bayer, etoricoxib / Generic mfg.
Journal: Relative efficacy and tolerability of etoricoxib, celecoxib, and naproxen in the treatment of osteoarthritis : A Bayesian network meta-analysis of randomized controlled trials based on patient withdrawal. (Pubmed Central) - May 11, 2017
Etoricoxib 30-60 mg, celecoxib 200-400 mg, and naproxen 1000 mg were more efficacious than placebo. However, there was no significant difference in efficacy and tolerability between the medications.
- | diphenhydramine/naproxen (BAY98-7111) / Bayer
New P1 trial: Morpheus PK: Compare Pharmacokinetic (PK) Profiles of Naproxen Sodium, Diphenhydramine Hydrochloride, and Naproxen Sodium and Diphenhydramine Hydrochloride Combination (clinicaltrials.gov) - Aug 14, 2012
P1, N=32, Completed, Sponsor: Bayer
- ||||||| diphenhydramine/naproxen (BAY98-7111) / Bayer
Trial completion, Metastases: Morpheus/DPHt: Evaluate Analgesic / Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain (clinicaltrials.gov) - Mar 7, 2012
P3, N=267, Completed, Sponsor: Bayer
However, there was no significant difference in efficacy and tolerability between the medications. Recruiting --> Completed
- ||||||| naproxen Sodium ER (BAYH6689) / Bayer
Trial completion: Actual Use Trial of Naproxen Sodium (clinicaltrials.gov) - Feb 2, 2012
P3, N=778, Completed, Sponsor: Bayer
Recruiting --> Completed Recruiting --> Completed
- |||||||||| diphenhydramine/naproxen (BAY98-7111) / Bayer
New P3 trial, Metastases: Morpheus/DPHt: Evaluate Analgesic / Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain (clinicaltrials.gov) - Dec 18, 2011
P3, N=267, Completed, Sponsor: Bayer
- ||||||| naproxen Sodium ER (BAYH6689) / Bayer
Trial completion: VERNE: Evaluate Efficacy and Safety of Extended Release (ER) Naproxen Sodium (clinicaltrials.gov) - Oct 25, 2011
P3, N=300, Completed, Sponsor: Bayer
Recruiting --> Completed Recruiting --> Completed
- ||||||| naproxen Sodium ER (BAYH6689) / Bayer
Trial completion: KEIFER SST: Self Selection Trial of Naproxen Sodium (clinicaltrials.gov) - Sep 12, 2011
P3, N=253, Completed, Sponsor: Bayer
Recruiting --> Completed Recruiting --> Completed
- |||||||||| naproxen Sodium ER (BAYH6689) / Bayer
New P3 trial: Actual Use Trial of Naproxen Sodium (clinicaltrials.gov) - Aug 31, 2011
P3, N=778, Completed, Sponsor: Bayer